Skip to main content

Table 1 Baseline demographic characteristics (prior to leuprolide acetate) of the 120 patients who received Bravelle® and the 118 patients who received Follistim®

From: Highly purified human-derived follicle-stimulating hormone (Bravelle®) has equivalent efficacy to follitropin-beta (Follistim ®) in infertile women undergoing in vitro fertilization

Parameter Bravelle® (n = 120) Follistim® (n = 118) P-value
Age (years) 32.0 ± 3.9 32.5 ± 3.7 0.330
Weight (lbs.) 137.1 ± 21.4 145.8 ± 27.8 0.008
Body mass index (kg/m2) 23.3 ± 3.5 24.5 ± 4.0 0.021
Serum FSH (mIU/mL) 6.3 ± 2.0 6.8 ± 2.1 0.077
Serum LH (mIU/mL) 5.0 ± 2.4 4.6 ± 1.9 0.145
Serum E2 (pg/mL) 43.1 ± 21.4 40.9 ± 20.9 0.420
Primary infertility diagnosis    
Tubal Factor 50.0 55.9 0.361
Endometriosis 17.5 14.4 0.508
Unexplained 28.3 22.9 0.341
Male factor 4.2 3.4 0.752
Fertility history (%)    
Full term birth (s) 23.3 31.4 0.087
Abortion(s)/miscarriage(s) 30.8 39.0 0.142
Gonadotropin cycles (excluding IVF/GIFT/PROST) 25.8 25.4 0.889
Previous IVF/GIFT/PROST 27.5 22.9 0.422
  1. Data are means ± SD.
\